Analysis of Pfizer's Dividend Safety
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy PFE?
Source: Fool
- Attractive Dividend Yield: Pfizer's dividend yield stands at 6.4%, which, while appealing to income-seeking investors, may also signal potential risks of a payout cut, particularly given the company's poor stock performance.
- Stock Price Recovery: The stock has climbed 25% over the past year, indicating a rebound potential, especially as blue-chip stocks like Pfizer attract more investors amid current market volatility and geopolitical tensions.
- Promising R&D Pipeline: Pfizer launched 11 pivotal studies in 2025 and plans to introduce 20 more this year, with PF'4404, a novel cancer drug, poised to be a significant growth driver if approved.
- Sustained Dividend Capability: Despite facing challenges such as product exclusivity loss, Pfizer has consistently increased its dividends over the past five years, suggesting it can maintain its dividend program while launching new products to drive sales growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.110
Low
24.00
Averages
28.56
High
35.00
Current: 27.110
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
The Importance of Pfizer's Drug Pipeline Analysis
- Vaccine Sales Fluctuation: Pfizer's COVID-19 vaccine propelled revenue from $41.6 billion in 2020 to $81.2 billion in 2021, but sales plummeted to around $58 billion in 2023, highlighting the direct impact of changing vaccine demand on the company's financials.
- Declining Stock Trend: Although Pfizer's revenue remains higher than pre-pandemic levels, its stock price has dropped approximately 29% over the past five years, reflecting market concerns about future growth potential, especially amid waning vaccine demand.
- Acquisition Strategy: Pfizer's acquisition of Metsera, which has no market drugs but weight-loss candidates in trials, and Seagen in 2023 to enhance its oncology business, demonstrates the company's proactive efforts to identify new growth drivers.
- Importance of Drug Pipeline: Pfizer's situation underscores the critical importance of a robust drug pipeline, as failure to adapt when patents expire or drug demand declines can lead to significant shareholder losses, emphasizing the necessity for ongoing innovation and R&D.
See More
White House Nominates Erica Schwartz as Next CDC Director
- Nomination of Schwartz: The White House is set to nominate Erica Schwartz, who served as deputy U.S. surgeon general under Trump, as the next CDC director, pending Trump's approval, indicating a desire for a nominee who minimizes controversy.
- CDC Leadership Vacancy: The CDC has been without permanent leadership since August when former director Susan Monarez was fired over disagreements with Trump's healthcare policies, which has impacted the agency's policy execution and public trust.
- Schwartz's Background: Schwartz holds a master's degree in public health and a law degree, and her experience as a Navy physician and chief medical officer at the U.S. Coast Guard may bring new perspectives and leadership to the CDC.
- Deputy Director Candidate: The Trump administration is also considering Sean Slovenski, a former Walmart executive, as Schwartz's deputy, further indicating the strategic reshaping of leadership within the CDC.
See More
High-Yield Stocks: Reliable Dividend Income Sources
- Telecom Stock Advantage: Verizon Communications boasts a dividend yield of 6.2%, significantly higher than the S&P 500's 1.2%, with an $8,000 investment generating approximately $500 annually, highlighting its stable financials and suitability for long-term holding.
- Logistics Giant Challenges: United Parcel Service offers a 6.4% dividend yield, and despite a 40% stock price drop over the past five years, it aims to improve margins by reducing business with Amazon, with an $8,000 investment yielding over $510 annually, showcasing its potential amid e-commerce growth.
- Pharmaceutical Industry Outlook: Pfizer's dividend yield stands at 6.3%, and although its stock has declined over 25% in five years, it has over 100 drug candidates and generated $7.8 billion in profit last year, indicating stability amid uncertainty, with an $8,000 investment yielding about $500 annually.
- Overall Income Analysis: Investing $8,000 in Verizon, UPS, and Pfizer could yield over $1,500 in total annual dividends, reflecting the significance of these high-yield stocks in a portfolio, making them ideal for income-seeking investors.
See More
Johnson & Johnson vs. Pfizer: The Future of Healthcare Stocks
- Successful Spin-off: Johnson & Johnson's spin-off of its slow-growing consumer health division into Kenvue in 2023 has led to enhanced operational efficiency, with revenue reaching $88.8 billion in 2024 and projected to grow to between $99.5 billion and $100.5 billion by 2026, indicating strong growth potential in the healthcare market.
- Pfizer's Revenue Challenges: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; despite efforts to strengthen its oncology pipeline through acquisitions like Seagen and Metsera, revenue is expected to remain flat in 2026, ranging from $59.5 billion to $62.5 billion, highlighting growth risks.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; although Pfizer appears undervalued with a lower forward P/E ratio, its lower future earnings expectations may signal risks, whereas Johnson & Johnson's 60+ years of consistent dividend growth suggests greater sustainability.
- Market Outlook Analysis: Amid concerns over inflation, AI bubbles, and geopolitical risks, Johnson & Johnson's broad product portfolio, steady cash flow, and reliable dividend payments position it as a focal point for investors seeking potential shareholder returns over the next decade.
See More
Market Performance Analysis of Johnson & Johnson and Pfizer
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and an expected range of $99.5 billion to $100.5 billion for 2026, indicating a clearer business focus and enhanced growth following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; while its drug development efforts, particularly in oncology and the acquisition of Seagen, suggest future growth potential, the short-term revenue stability remains a concern.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, compared to Johnson & Johnson's 2.1%; although Pfizer's yield appears more attractive, Johnson & Johnson's consistent dividend increases over the past 60 years reflect its financial stability and sustainability.
- Market Outlook Assessment: In the current economic climate, Johnson & Johnson demonstrates higher growth potential due to its diverse product portfolio and steady cash flow, leading analysts to favor its future earnings capability, making it a suitable focus for long-term investors.
See More
Stock Showdown: Johnson & Johnson vs. Pfizer
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and expected sales between $99.5 billion and $100.5 billion for 2026, indicating enhanced operational efficiency and growth potential following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; however, the company is actively developing new drugs, particularly bolstering its oncology segment through the acquisition of Seagen, with the global oncology drug market projected to grow from $286 billion in 2026 to $679 billion by 2034.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; despite Pfizer's lower P/E ratio, concerns about the sustainability of its dividend arise from stagnant revenue growth, whereas Johnson & Johnson's over 60 years of dividend increases suggest greater reliability for investors.
- Market Outlook Analysis: In the current economic climate, Johnson & Johnson demonstrates stronger market competitiveness due to its stable cash flow and increasing revenue, while Pfizer must rely on the success of its drug pipeline to maintain shareholder returns, prompting investors to carefully assess the investment value of each company.
See More
The Importance of Pfizer's Drug Pipeline Analysis
- Vaccine Sales Fluctuation: Pfizer's COVID-19 vaccine propelled revenue from $41.6 billion in 2020 to $81.2 billion in 2021, but sales plummeted to around $58 billion in 2023, highlighting the direct impact of changing vaccine demand on the company's financials.
- Declining Stock Trend: Although Pfizer's revenue remains higher than pre-pandemic levels, its stock price has dropped approximately 29% over the past five years, reflecting market concerns about future growth potential, especially amid waning vaccine demand.
- Acquisition Strategy: Pfizer's acquisition of Metsera, which has no market drugs but weight-loss candidates in trials, and Seagen in 2023 to enhance its oncology business, demonstrates the company's proactive efforts to identify new growth drivers.
- Importance of Drug Pipeline: Pfizer's situation underscores the critical importance of a robust drug pipeline, as failure to adapt when patents expire or drug demand declines can lead to significant shareholder losses, emphasizing the necessity for ongoing innovation and R&D.
See More
White House Nominates Erica Schwartz as Next CDC Director
- Nomination of Schwartz: The White House is set to nominate Erica Schwartz, who served as deputy U.S. surgeon general under Trump, as the next CDC director, pending Trump's approval, indicating a desire for a nominee who minimizes controversy.
- CDC Leadership Vacancy: The CDC has been without permanent leadership since August when former director Susan Monarez was fired over disagreements with Trump's healthcare policies, which has impacted the agency's policy execution and public trust.
- Schwartz's Background: Schwartz holds a master's degree in public health and a law degree, and her experience as a Navy physician and chief medical officer at the U.S. Coast Guard may bring new perspectives and leadership to the CDC.
- Deputy Director Candidate: The Trump administration is also considering Sean Slovenski, a former Walmart executive, as Schwartz's deputy, further indicating the strategic reshaping of leadership within the CDC.
See More
High-Yield Stocks: Reliable Dividend Income Sources
- Telecom Stock Advantage: Verizon Communications boasts a dividend yield of 6.2%, significantly higher than the S&P 500's 1.2%, with an $8,000 investment generating approximately $500 annually, highlighting its stable financials and suitability for long-term holding.
- Logistics Giant Challenges: United Parcel Service offers a 6.4% dividend yield, and despite a 40% stock price drop over the past five years, it aims to improve margins by reducing business with Amazon, with an $8,000 investment yielding over $510 annually, showcasing its potential amid e-commerce growth.
- Pharmaceutical Industry Outlook: Pfizer's dividend yield stands at 6.3%, and although its stock has declined over 25% in five years, it has over 100 drug candidates and generated $7.8 billion in profit last year, indicating stability amid uncertainty, with an $8,000 investment yielding about $500 annually.
- Overall Income Analysis: Investing $8,000 in Verizon, UPS, and Pfizer could yield over $1,500 in total annual dividends, reflecting the significance of these high-yield stocks in a portfolio, making them ideal for income-seeking investors.
See More
Johnson & Johnson vs. Pfizer: The Future of Healthcare Stocks
- Successful Spin-off: Johnson & Johnson's spin-off of its slow-growing consumer health division into Kenvue in 2023 has led to enhanced operational efficiency, with revenue reaching $88.8 billion in 2024 and projected to grow to between $99.5 billion and $100.5 billion by 2026, indicating strong growth potential in the healthcare market.
- Pfizer's Revenue Challenges: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; despite efforts to strengthen its oncology pipeline through acquisitions like Seagen and Metsera, revenue is expected to remain flat in 2026, ranging from $59.5 billion to $62.5 billion, highlighting growth risks.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; although Pfizer appears undervalued with a lower forward P/E ratio, its lower future earnings expectations may signal risks, whereas Johnson & Johnson's 60+ years of consistent dividend growth suggests greater sustainability.
- Market Outlook Analysis: Amid concerns over inflation, AI bubbles, and geopolitical risks, Johnson & Johnson's broad product portfolio, steady cash flow, and reliable dividend payments position it as a focal point for investors seeking potential shareholder returns over the next decade.
See More
Market Performance Analysis of Johnson & Johnson and Pfizer
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and an expected range of $99.5 billion to $100.5 billion for 2026, indicating a clearer business focus and enhanced growth following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; while its drug development efforts, particularly in oncology and the acquisition of Seagen, suggest future growth potential, the short-term revenue stability remains a concern.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, compared to Johnson & Johnson's 2.1%; although Pfizer's yield appears more attractive, Johnson & Johnson's consistent dividend increases over the past 60 years reflect its financial stability and sustainability.
- Market Outlook Assessment: In the current economic climate, Johnson & Johnson demonstrates higher growth potential due to its diverse product portfolio and steady cash flow, leading analysts to favor its future earnings capability, making it a suitable focus for long-term investors.
See More
Stock Showdown: Johnson & Johnson vs. Pfizer
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and expected sales between $99.5 billion and $100.5 billion for 2026, indicating enhanced operational efficiency and growth potential following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; however, the company is actively developing new drugs, particularly bolstering its oncology segment through the acquisition of Seagen, with the global oncology drug market projected to grow from $286 billion in 2026 to $679 billion by 2034.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, while Johnson & Johnson's yield stands at 2.1%; despite Pfizer's lower P/E ratio, concerns about the sustainability of its dividend arise from stagnant revenue growth, whereas Johnson & Johnson's over 60 years of dividend increases suggest greater reliability for investors.
- Market Outlook Analysis: In the current economic climate, Johnson & Johnson demonstrates stronger market competitiveness due to its stable cash flow and increasing revenue, while Pfizer must rely on the success of its drug pipeline to maintain shareholder returns, prompting investors to carefully assess the investment value of each company.
See More
